Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection

Wenjing Zai,Min Yang,Kuan Jiang,Juan Guan,Huijing Wang,Kongying Hu,Chao Huang,Jieliang Chen,Wei Fu,Changyou Zhan,Zhenghong Yuan
DOI: https://doi.org/10.1038/s41392-024-01871-8
IF: 39.3
2024-06-22
Signal Transduction and Targeted Therapy
Abstract:This study aimed to develop a pan-genotypic and multifunctional small interfering RNA (siRNA) against hepatitis B virus (HBV) with an efficient delivery system for treating chronic hepatitis B (CHB), and explore combined RNA interference (RNAi) and immune modulatory modalities for better viral control. Twenty synthetic siRNAs targeting consensus motifs distributed across the whole HBV genome were designed and evaluated. The lipid nanoparticle (LNP) formulation was optimized by adopting HO-PEG 2000 -DMG lipid and modifying the molar ratio of traditional polyethylene glycol (PEG) lipid in LNP prescriptions. The efficacy and safety of this formulation in delivering siHBV (tLNP/siHBV) along with the mouse IL-2 (mIL-2) mRNA (tLNP/siHBVIL2) were evaluated in the rAAV-HBV1.3 mouse model. A siRNA combination (terms "siHBV") with a genotypic coverage of 98.55% was selected, chemically modified, and encapsulated within an optimized LNP (tLNP) of high efficacy and security to fabricate a therapeutic formulation for CHB. The results revealed that tLNP/siHBV significantly reduced the expression of viral antigens and DNA (up to 3log 10 reduction; vs PBS) in dose- and time-dependent manners at single-dose or multi-dose frequencies, with satisfactory safety profiles. Further studies showed that tLNP/siHBVIL2 enables additive antigenic and immune control of the virus, via introducing potent HBsAg clearance through RNAi and triggering strong HBV-specific CD4 + and CD8 + T cell responses by expressed mIL-2 protein. By adopting tLNP as nucleic acid nanocarriers, the co-delivery of siHBV and mIL-2 mRNA enables synergistic antigenic and immune control of HBV, thus offering a promising translational therapeutic strategy for treating CHB.
biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The paper aims to develop a pan-genotypic and multifunctional small interfering RNA (siRNA) therapy for the treatment of chronic hepatitis B (CHB) and achieve effective control of the hepatitis B virus (HBV) through an efficient delivery system. The study also explores the combination of RNA interference (RNAi) with immunomodulatory approaches to better control the virus. Specifically, the researchers designed and evaluated 20 small interfering RNAs targeting conserved regions of the HBV genome and optimized lipid nanoparticle (LNP) formulations to improve delivery efficiency and safety. Experimental results showed that the optimized LNP-encapsulated siRNA (tLNP/siHBV) could significantly reduce the expression of viral antigens and DNA, exhibiting dose- and time-dependent effects with single or multiple administrations. Furthermore, additional studies demonstrated that co-delivery of mouse interleukin-2 (mIL-2) mRNA with siRNA (tLNP/siHBVIL2) could enhance viral antigen clearance and boost immune control by triggering strong HBV-specific CD4+ and CD8+ T cell responses. In conclusion, the study proposes a new strategy based on the co-delivery of tLNP-encapsulated siHBV and mIL-2 mRNA, providing a promising translational therapeutic approach for the treatment of chronic hepatitis B.